ImmunityBio (IBRX) News Today $3.07 -0.12 (-3.76%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$3.04 -0.03 (-1.14%) As of 06/13/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IBRX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period ImmunityBio (NASDAQ:IBRX) Shares Gap Down - Here's WhyImmunityBio (NASDAQ:IBRX) Shares Gap Down - Time to Sell?June 13 at 1:04 PM | marketbeat.comImmunityBio: Lymphopenia Opportunity Could Provoke Short SqueezeJune 13 at 12:47 AM | seekingalpha.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $670,000 Position in ImmunityBio, Inc. (NASDAQ:IBRX)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its holdings in ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 83.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 261,734 shares of the company'sJune 12 at 3:28 AM | marketbeat.comImmunityBio (IBRX) Jumps 18% on Anktiva Access ExpansionJune 10, 2025 | msn.comImmunityBio (NASDAQ:IBRX) Shares Gap Up - Still a Buy?ImmunityBio (NASDAQ:IBRX) Shares Gap Up - Here's What HappenedJune 9, 2025 | marketbeat.com15 Stocks That Stole The Show Last WeekJune 8, 2025 | insidermonkey.comMillennium Management LLC Reduces Position in ImmunityBio, Inc. (NASDAQ:IBRX)Millennium Management LLC lessened its stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 79.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 234,078 shares of the company's stock after selling 882,687 shares duringJune 8, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Receives "Buy" Rating from HC WainwrightJune 6, 2025 | americanbankingnews.comImmunityBio (NASDAQ:IBRX) Trading Up 6.3% - Should You Buy?ImmunityBio (NASDAQ:IBRX) Shares Up 6.3% - Still a Buy?June 4, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for ImmunityBio (NASDAQ:IBRX)HC Wainwright restated a "buy" rating and issued a $8.00 price target on shares of ImmunityBio in a research report on Wednesday.June 4, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Gap Up - Here's WhyImmunityBio (NASDAQ:IBRX) Shares Gap Up - What's Next?June 3, 2025 | marketbeat.comImmunityBio receives FDA Expanded Access authorization for Cancer BioShieldJune 3, 2025 | finance.yahoo.comASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic CancerJune 3, 2025 | businesswire.comImmunityBio (NASDAQ:IBRX) Receives Buy Rating from D. Boral CapitalD. Boral Capital restated a "buy" rating and issued a $30.00 price objective on shares of ImmunityBio in a report on Tuesday.June 3, 2025 | marketbeat.comImmunityBio gets FDA expanded access authorization to treat lymphopenia with AnktivaJune 2, 2025 | msn.comImmunityBio Sees Unusually Large Options Volume (NASDAQ:IBRX)ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) was the target of unusually large options trading activity on Monday. Investors bought 6,205 call options on the company. This represents an increase of 42% compared to the average daily volume of 4,357 call options.June 2, 2025 | marketbeat.comDeutsche Bank AG Reduces Stock Position in ImmunityBio, Inc. (NASDAQ:IBRX)Deutsche Bank AG cut its stake in ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 63.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 123,057 shares of the company's stock after selling 210,462 shJune 1, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Trading 6.3% Higher - Time to Buy?ImmunityBio (NASDAQ:IBRX) Stock Price Up 6.3% - Should You Buy?May 30, 2025 | marketbeat.comWhy ImmunityBio, Inc. (IBRX) Surged On ThursdayMay 30, 2025 | msn.comImmunityBio's (IBRX) Buy Rating Reaffirmed at D. Boral CapitalD. Boral Capital reiterated a "buy" rating and set a $30.00 price objective on shares of ImmunityBio in a research report on Wednesday.May 29, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Gap Up - Time to Buy?ImmunityBio (NASDAQ:IBRX) Shares Gap Up - Time to Buy?May 28, 2025 | marketbeat.comWoodline Partners LP Buys 3,002,622 Shares of ImmunityBio, Inc. (NASDAQ:IBRX)Woodline Partners LP raised its stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 682.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 3,442,440 shares of the company's stock after purchasing an additional 3,002,622 sharesMay 25, 2025 | marketbeat.com10 Firms Drenched in Red TodayMay 23, 2025 | insidermonkey.comImmunityBio, Inc. (NASDAQ:IBRX) Shares Bought by Rafferty Asset Management LLCRafferty Asset Management LLC raised its position in ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 20.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 549,905 shares of the company's stoMay 23, 2025 | marketbeat.comPiper Sandler Upgrades ImmunityBio (IBRX) to Overweight, Lifts PTMay 22, 2025 | msn.comImmunityBio (NASDAQ:IBRX) Rating Increased to Overweight at Piper SandlerPiper Sandler upgraded ImmunityBio from a "neutral" rating to an "overweight" rating and set a $5.00 target price on the stock in a research note on Tuesday.May 22, 2025 | marketbeat.comJim Cramer’s Recent Thoughts on These 15 StocksMay 22, 2025 | insidermonkey.comJim Cramer Notes ImmunityBio (IBRX) Has “Been Losing Money Forever”May 20, 2025 | msn.comImmunityBio upgraded to Overweight at Piper Sandler on Anktiva successMay 20, 2025 | msn.comWhy ImmunityBio, Inc. (IBRX) Surged Last WeekMay 20, 2025 | msn.comTang Capital Management LLC Makes New $7.20 Million Investment in ImmunityBio, Inc. (NASDAQ:IBRX)Tang Capital Management LLC bought a new position in ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 2,814,192 shares of the company's stock, valued at approximately $7,204,000.May 20, 2025 | marketbeat.comImmunityBio Short Interest Hits 2-Month High, Yet Retail Traders Bet On The UpsideMay 19, 2025 | msn.comEarnings Update: Here's Why Analysts Just Lifted Their ImmunityBio, Inc. (NASDAQ:IBRX) Price Target To US$13.00May 14, 2025 | finance.yahoo.comImmunityBio (NASDAQ:IBRX) Stock Price Up 15.1% - Still a Buy?ImmunityBio (NASDAQ:IBRX) Trading 15.1% Higher - Time to Buy?May 14, 2025 | marketbeat.comImmunityBio's (IBRX) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $8.00 price objective on shares of ImmunityBio in a research note on Monday.May 14, 2025 | marketbeat.comD. Boral Capital Reaffirms Buy Rating for ImmunityBio (NASDAQ:IBRX)D. Boral Capital reissued a "buy" rating and issued a $30.00 price objective on shares of ImmunityBio in a report on Monday.May 14, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Issues Earnings ResultsImmunityBio (NASDAQ:IBRX - Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.03).May 14, 2025 | marketbeat.comWhy These 10 Stocks Soared by Double Digits TodayMay 14, 2025 | insidermonkey.comWhy ImmunityBio, Inc. (IBRX) Soared TodayMay 13, 2025 | msn.comImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-codeMay 12, 2025 | businesswire.comFirst Trust Advisors LP Has $428,000 Stock Position in ImmunityBio, Inc. (NASDAQ:IBRX)First Trust Advisors LP cut its stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 77.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 167,200 shares of the company's stock after selling 589,609 shares during the peMay 12, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Reaches New 12-Month Low - What's Next?ImmunityBio (NASDAQ:IBRX) Sets New 1-Year Low - What's Next?May 8, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Gap Down - What's Next?ImmunityBio (NASDAQ:IBRX) Shares Gap Down - Time to Sell?May 7, 2025 | marketbeat.comImmunityBio Slides Following FDA Refusal-to-File LetterMay 6, 2025 | marketwatch.comImmunityBio Stock Tumbles 18% After FDA Issues Refuse To File Letter: But Retail’s PositiveMay 6, 2025 | msn.comImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLAMay 5, 2025 | seekingalpha.comImmunityBio Requests Meeting With FDA Over Rejected Bladder Treatment ApplicationMay 5, 2025 | marketwatch.comImmunityBio stock sinks after FDA issues RTF letterMay 5, 2025 | in.investing.comImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency's Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025May 5, 2025 | businesswire.comMarshall Wace LLP Makes New $615,000 Investment in ImmunityBio, Inc. (NASDAQ:IBRX)Marshall Wace LLP bought a new stake in ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 240,311 shares of the company's stock, valued at approximately $615,000. SMay 5, 2025 | marketbeat.com Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address IBRX Media Mentions By Week IBRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IBRX News Sentiment▼0.970.89▲Average Medical News Sentiment IBRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IBRX Articles This Week▼84▲IBRX Articles Average Week Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MRNA News ASND News VTRS News QGEN News BPMC News ROIV News RVMD News BBIO News ELAN News VRNA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IBRX) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunityBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunityBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IBRX Stock Free IBRX Stock Alerts